Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
← catalyst calendarNCT06812988 · readout in 253 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
84estimated
Sites
24
Countries
Argentina, Australia, Brazil +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-28 | actual | When the study began enrolling |
| Primary completion | 2027-04-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 1 Diabetes Mellitus
Interventions
- Drug: Brivekimig
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline to Week 26 in mean 2-hour mixed meal tolerance test (MMTT) stimulated C-peptide concentration
measured From Baseline to Week 26
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed